History of Recordati Group
|1926||The company is founded.|
|1953||Recordati is founded in Correggio –Emilia Region – as „Laboratorio Farmacologico Reggiano” by G. Recordati.|
|1961||Recordati is transferred to its new seat in Milan.|
|1984||Signing an exclusive license agreement with Syntex (now Roche), renewed regularly until 2005.|
|1995||Recordati is listed on the Italian Stock exchange for the first time.|
|1997||Opening the Spanish branch, now known as Recordati Espana in Madrid.|
|1999||Launch of Zanidip® preparation (lercanidipine).|
|2000||Acquisition of Doms Adrian, a French pharmaceutical company – as a result presence on two European markets.|
|2001||Acquisition of Bouchara, a French pharmaceutical group.|
|2002||Establishment of Bouchara Recordati in France, following the restructuring of the French company in 1999 and 2000.|
|2003||UK Medicines Control Agency issues a document (product license) confirming the market authorization for Zanidip® (lercanidipine) in 20 mg tablets.|
|2004||20 mg dose of lercanidipine is introduced in Germany, France and Australia.|
|2006||Acquisition of Merckle Recordati in Germany. Share distribution 4:1. Four new shares replace each issued share. Recordati Pharmaceuticals in Great Britain is established. Recordati Hellas Pharmaceuticals SA in Greece is established. A new branch is opened in Ireland.|
|2007||Acquisition of pharmaceutical operations of Grupo Jaba in Portugal. BfArM (German Drug Agency) authorizes Zanitek®/Zanipress®, a combination of lercanidipine and enalapril in fixed proportions.
Launch of Zanipress®. Acquisition of Orphan Europe.
|2008||Acquisition of FIC and FIC Médical, a pharmaceutical chain operating in Russia and other countries of Commonwealth of Independent States. Acquisition of Yeni Ilaç, a Turkish pharmaceutical company.|
|2009||Acquisition of Herbacos-Bofarma, a pharmaceutical company operating in Czech Republic and in Slovakia.|
|2010||Market authorization in Europe of Urorec® and Silodyx™ 4mg, 8 mg (in hard capsules), designated for treatment of benign prostatic hyperplasia. Authorization of Carbaglu® (carglumic acid) by Food and Drugs Agency in USA for treatment of N-acetylglutamate synthase (NAGS) deficiency. Acquisition of ArtMed International, a company distributing pharmaceutical products in Romania. Market authorizations in Europe for pitavastatin (Livazo®, Alipza® and other preparations). Signing a European license agreement with American Nymox Pharmaceutical Corporation for development and commercialization of NX-1207, which is in phase 3 of clinical research. The drug is applied in treating the symptoms of benign prostatic hyperplasia (BPH).|
Authorization in Europe for extended application of Carbaglu® preparation (carglumic acid) in patients with hyperammonemia which occurs in three main types of organ acidosis. Acquisition of Turkish pharmaceutical company Frik Ilaç.
|2012||Recordati Polska is established, with its headquarters in Warsaw – starting up business in Poland and acquisition of Farma-Projekt, a Polish pharmaceutical company. Acquisition of OTC products in Germany, Poland, Russia and Italy. Purchase of product portfolio designated for treating rare diseases in USA. Signing a European license agreement with Erytech for Graspa® (L-asparaginase closed in homologous red blood cells) for treating acute lymphoblastic leukemia and acute myeloid leukemia.|
|2013||Acquisition of 90% of share capital of Opalia Pharma S.A., a Tunisian pharmaceutical company seated in Aryanah. Acquisition of 100% of share capital of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company seated in Madrid and a production plant in Utebo, Saragossa.|